Navigation Links
Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60
Date:8/26/2014

$3 billion.

Forward-Looking Statements
Except for historical information contained herein, this press release contains "forward-looking statements" (including, but not limited to, statements that contain words such as "will," "believe," "plan," "anticipate," "expect," "estimate") within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: our plans regarding our initial clinical trial, including the timing for initiation and completion, the proposed trial design, the principal investigator, phased enrollment and anticipated data; our plans regarding future clinical trials including potential pivotal trials, our understanding and beliefs regarding the anticipated benefits of our lead drug candidate RUT58-60 to patients and the healthcare system; and our beliefs as to the potential size of the target market for RUT58-60. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading "Risk Factors" contained in the documents filed by Ruthigen with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of the release, and Ruthigen disclaims any obligation to update the information contained in this press release as new information becomes available.


'/>"/>
SOURCE Ruthigen, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60
2. Ruthigen Reports Fiscal First Quarter 2015 Financial Results
3. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
4. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
5. Nephros Receives 510(k) Clearance for Hemodiafiltration System
6. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
7. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
8. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, announced today that it ... Report on Form 20-F that included audited financial statements ... version of Mindray,s Annual Report on Form 20-F is ...
... 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... the European League Against Rheumatism (EULAR) 2011 Annual Congress.  The ... London, United Kingdom, and will feature the abstracts as two ... scheduled oral presentation and the poster session will address the ...
Cached Medicine Technology:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2
(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
... recurrence after five-year mark, but numbers aren,t as high as ... News) -- The risk of relapse can linger for some ... doctors call systemic therapy, a new study found. , But, ... bright spot: the risk may not be as dire as ...
... Urged to End Role as It Did with ... For the second time in,recent weeks, international ... to withdraw its sponsorship and promotion of a ... company,s activities appear,to violate national law., Last ...
... SMBL ) announced today Stephen Hughes, Chairman and ... presentation at the Canaccord,Adams Global Growth Conference in Boston, ... Smart Balance,s presentation will be approximately 30 minutes ... questions, but,listeners will be able to hear the question-and-answer ...
... study fails to settle question about best treatment for ... The latest update from a European study that has ... decade leaves the debate about the advantages of aggressive ... survival seen for men who underwent surgery to remove ...
... Holland America Line has surpassed the,million-dollar mark in ... its On Deck for the Cure program, earning it ... will celebrate the milestone,this week with special receptions and ... corporate headquarters in Seattle., Since the program began ...
... Internet shopping today offers many benefits. You can research ... and purchase most anything by clicking a mouse. But ... the Internet, bypassing a traditional office visit or conversation ... Mayo Clinic Proceedings , researchers from Utah and several ...
Cached Medicine News:Health News:Risk of Breast Cancer Relapse Can Linger 2Health News:Risk of Breast Cancer Relapse Can Linger 3Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 2Health News:Philip Morris International Caught in Philippines in Another Concert Sponsorship 3Health News:Smart Balance to Webcast Presentation at Canaccord Adams Global Growth Conference 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 2Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 3Health News:Holland America Line Program Surpasses $1 Million Raised for Susan G. Komen for the Cure(R) 4Health News:Researchers examine safety of Internet prescriber service providing erectile dysfunction medications 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
Medicine Products: